302440 — SK Bioscience Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMid CapSucker Stock

Annual income statement for SK Bioscience Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	225,611	929,001	456,726	369,506	267,545
Cost of Revenue
Gross Profit	95,342	570,283	239,611	142,243	30,976
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	187,900	454,781	341,712	382,647	390,567
Operating Profit	37,710	474,220	115,014	-13,141	-123,022
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	37,293	471,128	141,733	7,327	-89,107
Provision for Income Taxes
Net Income After Taxes	32,890	355,139	122,452	22,318	-50,117
Net Income Before Extraordinary Items
Net Income	32,890	355,139	122,452	22,318	-50,117
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	32,890	355,139	122,452	22,318	-50,117
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	530	4,810	1,595	300	-899
Dividends per Share